5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice

Tang,Haiying; Xiang,Dan; Wang,Feng; Mao,Jingwei; Tan,Xiaoyan; Wang,Yingde

doi:10.3892/mmr.2017.6153

5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice

Authors:
- Haiying Tang
- Dan Xiang
- Feng Wang
- Jingwei Mao
- Xiaoyan Tan
- Yingde Wang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Liver Disease, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning 110000, P.R. China, State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning 116023, P.R. China
Published online on: January 26, 2017 https://doi.org/10.3892/mmr.2017.6153
Pages: 1117-1122
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The targeting of 5-aminosalicylic acid (5-ASA), a first-line therapeutic agent for mild to moderate active ulcerative colitis (UC), to the site of inflammation has remained a challenge and an unmet requirement in the treatment of UC. However, nanoscale carriers for targeted drug delivery are promising for pharmacotherapy, and nanoparticles improve the pharmacokinetics of the loaded therapeutics based on their physical properties. To design and prepare 5‑ASA‑loaded silicon dioxide nanoparticles (5‑ASA‑SiO2 NPs), a micro‑emulsion method was conducted, and their respective therapeutic effects were validated in a mouse model of UC. Cytotoxicity of 5‑ASA‑SiO2 NPs was detected in vitro using the Cell Counting Kit‑8 method. The therapeutic effect of 5‑ASA‑SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor‑α (TNF‑α) and interleukin‑6 (IL‑6). SiO2 NPs were successfully prepared, and cytotoxicity of 5‑ASA‑SiO2 NPs was identified as being similar to 5‑ASA and SiO2 NPs. DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group. DAI in the high dosage and 5‑ASA‑SiO2 NP groups also demonstrated a significant improvement when compared with the normal dosage group. However, MPO, serum IL‑6 and TNF‑α levels in normal dosage, high dosage and 5‑ASA‑SiO2 NPs groups were significantly lower than in the model group, and these indexes in the high dosage group and 5‑ASA‑SiO2 NP group were significantly lower than that in the normal dosage group. Expression of IL‑6 and TNF‑α mRNA in colonic mucosa in the normal dosage, high dosage and 5‑ASA‑SiO2 NP group was significantly lower than that in the model group. Colonic mucosal IL‑6 and TNF‑α mRNA expression in the high dosage and 5‑ASA‑SiO2 NP groups was significantly lower than that in the normal dosage group (P<0.05). In conclusion, 5‑ASA‑SiO2 NPs are a selective drug release system that target the inflamed colon, characteristics of UC, and can greatly increase therapeutic efficacy in UC.

View Figures

View References

1	Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimiol EI, Panaccione R, Ghosh S, Barkema HW and Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematice review. Gastroenterology. 142:46–54, e42; quiz e30. 2012. View Article : Google Scholar : PubMed/NCBI
2	Lakatos L and Lakatos LP: Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J. 82:332–337. 2006. View Article : Google Scholar : PubMed/NCBI
3	de Pineton Chambrun G, Peyrin-Biroulet L, Lémann M and Colombel JF: Clinical implications of mucosal healing for the mangement of IBD. Nat Rev Gastroenterol Hepatol. 7:15–29. 2010. View Article : Google Scholar : PubMed/NCBI
4	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
5	Min Wang, Chen Chen, Jiping Ma and Jie Xu: Preparation of superhydrophobic cauliflower-like silica nanosheres with tunable water adhesion. J Mater Chem. 21:6962–6967. 2011. View Article : Google Scholar
6	Hoffmann JC, Pawlowski NN, Kühl AA, Höhne W and Zeitz M: Animal models of inflammatory bowel disease: An overview. Pathobiology. 70:121–130. 2002.-2003. View Article : Google Scholar : PubMed/NCBI
7	Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA and Endres S: Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther. 292:22–30. 2000.PubMed/NCBI
8	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
9	Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N, Sasaki S, Saitoh O and Katsu K: Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
10	Lamprecht A: IBD: Selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol and Hepatolo. 7:311–312. 2010. View Article : Google Scholar
11	Hock SC, Ying YM and Wah CL: A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol. 65:177–195. 2011.PubMed/NCBI
12	Borbat PP, Costa-Filho AJ, Earle KA, Moscicki JK and Freed JH: Electron spin resonance in studies of membranes and proteins. Science. 291:266–269. 2001. View Article : Google Scholar : PubMed/NCBI
13	Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaïli L, Refouvelet B, Pellequer Y and Lamprecht A: 5-amio salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 123:211–218. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lamprecht A, Yamamoto H, Takeuchi H and Kawashima Y: Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 315:196–202. 2005. View Article : Google Scholar : PubMed/NCBI
15	Moulari B, Pertuit D, Pellequer Y and Lamprecht A: The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 29:4554–4560. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kshirsagar SJ, Bhalekar MR, Patel JN, Mohapatra SK and Shewale NS: Preparation and characterization of nanocapsules for colon-targeted drug delivery system. Pharm Dev Technol. 17:607–613. 2012. View Article : Google Scholar : PubMed/NCBI
17	Lamprecht A, Schäfer U and Lehr CM: Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 18:788–793. 2001. View Article : Google Scholar : PubMed/NCBI
18	Schmidt C, Lautenschlaeger C, Collnot EM, Schumann M, Bojarski C, Schulzke JD, Lehr CM and Stallmach A: Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: A first in vivo study in human patients. J Control Release. 165:139–145. 2013. View Article : Google Scholar : PubMed/NCBI
19	Walsh AJ, Bryant RV and Travis SP: Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 13:567–579. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, An P, Liu SQ and Yu HG: Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm. 2006:926422006. View Article : Google Scholar : PubMed/NCBI
21	Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein MI and Pellecchia C: Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol. 87:1447–1452. 1992.PubMed/NCBI
22	Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y and Lehr CM: Biodegradable nanoparticles for the targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 299:775–781. 2001.PubMed/NCBI
23	Niebel W, Walkenbach K, Béduneau A, Pellequer Y and Lamprecht A: Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Release. 160:659–665. 2012. View Article : Google Scholar : PubMed/NCBI
24	Meissner Y, Pellequer Y and Lamprecht A: Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int J Pharm. 316:138–143. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ng SC: Epidemiology of inflammatory bowel disease: Focus on Asia. Best Pract Res Clin Gastroenterol. 28:363–372. 2014. View Article : Google Scholar : PubMed/NCBI